tiprankstipranks
Trending News
More News >
NeuroPace (NPCE)
NASDAQ:NPCE
US Market

NeuroPace (NPCE) Stock Forecast & Price Target

Compare
123 Followers
See the Price Targets and Ratings of:

NPCE Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
NeuroPace
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NPCE Stock 12 Month Forecast

Average Price Target

$17.40
▲(32.32%Upside)
Based on 6 Wall Street analysts offering 12 month price targets for NeuroPace in the last 3 months. The average price target is $17.40 with a high forecast of $20.00 and a low forecast of $16.00. The average price target represents a 32.32% change from the last price of $13.15.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","9":"$9","13":"$13","17":"$17","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.04,13.575384615384614,14.11076923076923,14.646153846153846,15.18153846153846,15.716923076923077,16.252307692307692,16.787692307692307,17.323076923076922,17.85846153846154,18.393846153846155,18.92923076923077,19.464615384615385,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.04,13.375384615384615,13.71076923076923,14.046153846153846,14.38153846153846,14.716923076923075,15.052307692307691,15.387692307692307,15.723076923076922,16.058461538461536,16.39384615384615,16.729230769230767,17.064615384615383,{"y":17.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.04,13.267692307692307,13.495384615384614,13.723076923076922,13.95076923076923,14.178461538461537,14.406153846153845,14.633846153846154,14.861538461538462,15.089230769230769,15.316923076923077,15.544615384615383,15.772307692307692,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.99,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.92,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.29,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$20.00Average Price Target$17.40Lowest Price Target$16.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NPCE
TipRanks AITipRanks
Not Ranked
TipRanks
$13
Hold
-1.14%
Downside
Reiterated
06/05/25
NeuroPace's overall score reflects strong revenue growth and positive corporate events, yet is weighed down by significant financial risks and valuation challenges. The earnings call provided a positive outlook, but the company's high debt levels and negative cash flow remain critical concerns.
Lake Street Analyst forecast on NPCE
Frank TakkinenLake Street
Lake Street
$20
Buy
52.09%
Upside
Reiterated
06/05/25
NeuroPace (NPCE) Gets a Buy from Lake Street
Cantor Fitzgerald Analyst forecast on NPCE
Ross OsbornCantor Fitzgerald
Cantor Fitzgerald
$16
Buy
21.67%
Upside
Reiterated
06/02/25
Cantor Fitzgerald Sticks to Their Buy Rating for NeuroPace (NPCE)
Leerink Partners Analyst forecast on NPCE
Mike KratkyLeerink Partners
Leerink Partners
$18$16
Buy
21.67%
Upside
Reiterated
05/28/25
NeuroPace's Promising Prospects: Buy Rating Affirmed Despite Initial Study Setback
H.C. Wainwright Analyst forecast on NPCE
Yi ChenH.C. Wainwright
H.C. Wainwright
$18
Buy
36.88%
Upside
Initiated
05/28/25
Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal
Wells Fargo Analyst forecast on NPCE
Vik ChopraWells Fargo
Wells Fargo
$17
Buy
29.28%
Upside
Reiterated
05/27/25
NeuroPace: Buy Rating Affirmed Amid Promising NAUTILUS Study Outcomes and Favorable FDA Engagement
J.P. Morgan Analyst forecast on NPCE
Rohin K PatelJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/27/25
Optimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential
UBS
$17
Buy
29.28%
Upside
Initiated
01/21/25
Sustainable DD We initiate coverage of NPCE with a Buy rating and $17 PT. We view NPCE's RNS (responsive neuromodulation system) technology as providing a differentiated, and clinically proven interventional solution to address the vastly undertreated and underpenetrated DRE (drug resistant epilepsy) market. Ultimately, we believe NPCE shares should see multiple expansion over the next twelve months as the company is on the verge of TAM expanding catalysts in the 2H25 timeframe that we believe should drive a growth inflection. Our above consensus ~22% top-line CAGR (vs.
Morgan Stanley Analyst forecast on NPCE
Andrew RanieriMorgan Stanley
Morgan Stanley
$8
Hold
-39.16%
Downside
Reiterated
11/13/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zai Lab (NASDAQ: ZLAB), NeuroPace (NASDAQ: NPCE) and CervoMed (NASDAQ: CRVO)
Wolfe Research Analyst forecast on NPCE
Michael PolarkWolfe Research
Wolfe Research
$16$14
Buy
6.46%
Upside
Reiterated
08/14/24
NeuroPace Inc (NPCE) PT Lowered to $14 at Wolfe ResearchWolfe Research analyst Mike Polark lowered the price target on NeuroPace Inc (NASDAQ: NPCE) to $14.00 (from $16.00) while maintaining a Outperform rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NPCE
TipRanks AITipRanks
Not Ranked
TipRanks
$13
Hold
-1.14%
Downside
Reiterated
06/05/25
NeuroPace's overall score reflects strong revenue growth and positive corporate events, yet is weighed down by significant financial risks and valuation challenges. The earnings call provided a positive outlook, but the company's high debt levels and negative cash flow remain critical concerns.
Lake Street Analyst forecast on NPCE
Frank TakkinenLake Street
Lake Street
$20
Buy
52.09%
Upside
Reiterated
06/05/25
NeuroPace (NPCE) Gets a Buy from Lake Street
Cantor Fitzgerald Analyst forecast on NPCE
Ross OsbornCantor Fitzgerald
Cantor Fitzgerald
$16
Buy
21.67%
Upside
Reiterated
06/02/25
Cantor Fitzgerald Sticks to Their Buy Rating for NeuroPace (NPCE)
Leerink Partners Analyst forecast on NPCE
Mike KratkyLeerink Partners
Leerink Partners
$18$16
Buy
21.67%
Upside
Reiterated
05/28/25
NeuroPace's Promising Prospects: Buy Rating Affirmed Despite Initial Study Setback
H.C. Wainwright Analyst forecast on NPCE
Yi ChenH.C. Wainwright
H.C. Wainwright
$18
Buy
36.88%
Upside
Initiated
05/28/25
Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal
Wells Fargo Analyst forecast on NPCE
Vik ChopraWells Fargo
Wells Fargo
$17
Buy
29.28%
Upside
Reiterated
05/27/25
NeuroPace: Buy Rating Affirmed Amid Promising NAUTILUS Study Outcomes and Favorable FDA Engagement
J.P. Morgan Analyst forecast on NPCE
Rohin K PatelJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/27/25
Optimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential
UBS
$17
Buy
29.28%
Upside
Initiated
01/21/25
Sustainable DD We initiate coverage of NPCE with a Buy rating and $17 PT. We view NPCE's RNS (responsive neuromodulation system) technology as providing a differentiated, and clinically proven interventional solution to address the vastly undertreated and underpenetrated DRE (drug resistant epilepsy) market. Ultimately, we believe NPCE shares should see multiple expansion over the next twelve months as the company is on the verge of TAM expanding catalysts in the 2H25 timeframe that we believe should drive a growth inflection. Our above consensus ~22% top-line CAGR (vs.
Morgan Stanley Analyst forecast on NPCE
Andrew RanieriMorgan Stanley
Morgan Stanley
$8
Hold
-39.16%
Downside
Reiterated
11/13/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zai Lab (NASDAQ: ZLAB), NeuroPace (NASDAQ: NPCE) and CervoMed (NASDAQ: CRVO)
Wolfe Research Analyst forecast on NPCE
Michael PolarkWolfe Research
Wolfe Research
$16$14
Buy
6.46%
Upside
Reiterated
08/14/24
NeuroPace Inc (NPCE) PT Lowered to $14 at Wolfe ResearchWolfe Research analyst Mike Polark lowered the price target on NeuroPace Inc (NASDAQ: NPCE) to $14.00 (from $16.00) while maintaining a Outperform rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NeuroPace

1 Month
xxx
Success Rate
7/10 ratings generated profit
70%
Average Return
+1.15%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +1.15% per trade.
3 Months
xxx
Success Rate
16/23 ratings generated profit
70%
Average Return
+28.61%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +28.61% per trade.
1 Year
Frank TakkinenLake Street
Success Rate
17/23 ratings generated profit
74%
Average Return
+52.93%
reiterated a buy rating 5 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 73.91% of your transactions generating a profit, with an average return of +52.93% per trade.
2 Years
xxx
Success Rate
18/23 ratings generated profit
78%
Average Return
+76.89%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 78.26% of your transactions generating a profit, with an average return of +76.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NPCE Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
5
7
11
12
8
Buy
10
10
4
14
15
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
17
15
26
23
In the current month, NPCE has received 23 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NPCE average Analyst price target in the past 3 months is 17.40.
Each month's total comprises the sum of three months' worth of ratings.

NPCE Financial Forecast

NPCE Earnings Forecast

Next quarter’s earnings estimate for NPCE is -$0.22 with a range of -$0.27 to -$0.17. The previous quarter’s EPS was -$0.21. NPCE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year NPCE has Outperformed its overall industry.
Next quarter’s earnings estimate for NPCE is -$0.22 with a range of -$0.27 to -$0.17. The previous quarter’s EPS was -$0.21. NPCE beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year NPCE has Outperformed its overall industry.

NPCE Sales Forecast

Next quarter’s sales forecast for NPCE is $23.09M with a range of $22.70M to $23.69M. The previous quarter’s sales results were $22.52M. NPCE beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year NPCE has Outperformed its overall industry.
Next quarter’s sales forecast for NPCE is $23.09M with a range of $22.70M to $23.69M. The previous quarter’s sales results were $22.52M. NPCE beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year NPCE has Outperformed its overall industry.

NPCE Stock Forecast FAQ

What is NPCE’s average 12-month price target, according to analysts?
Based on analyst ratings, NeuroPace’s 12-month average price target is 17.40.
    What is NPCE’s upside potential, based on the analysts’ average price target?
    NeuroPace has 32.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NPCE a Buy, Sell or Hold?
          NeuroPace has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is NeuroPace’s price target?
            The average price target for NeuroPace is 17.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 32.32% Increase from the current price of $13.15.
              What do analysts say about NeuroPace?
              NeuroPace’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of NPCE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis